Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 2Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 16INDUSTRY 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Specimen Handling 39Magnetic Resonance Spectroscopy 30Carboplatin 14Biopsy 14Radiation 13Cyclophosphamide 13Radiotherapy 11daratumumab 10Vincristine 10Dexamethasone 10Surgical Procedures, Operative 9Etoposide 9Lenalidomide 8X-Rays 7Observation 7Leucovorin 7Irinotecan 7Doxorubicin 7Cisplatin 7durvalumab 6dexamethasone acetate 6dexamethasone 21-phosphate 6auricularum 6Watchful Waiting 6Radiosurgery 6Docetaxel 6Calcium Dobesilate 6pembrolizumab 5Stem Cell Transplantation 5Standard of Care 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × NETWORK × isatuximab × Clear all
NCT06182774 2026-05-12

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Canadian Cancer Trials Group

Phase 3 Recruiting
570 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡